EPICS: Leukemia in 2020 and Beyond

Chair: Elias Jabbour, MD

Virtual Meeting Part 1
Date: September 14, 2020
Virtual Start Time (3-hour duration): 5.00 PM EDT/4.00 PM CDT/3.00 PM MDT/2.00 PM PDT

AGENDA

Time (CDT)	Topic	Speaker/Moderator
4.00 PM – 4.10 PM 10 min	Welcome and Introductions	Elias Jabbour, MD
4.10 PM – 4.20 PM 10 min	**CML: First-Line TKI Landscape** (including RFS/TFR)	Javier Pinilla, MD, PhD
4.20 PM – 4.45 PM 25 min	**Key Questions and Topics for Discussion** • How do patient comorbidities factor into choice of TKI? • Should combination approaches with allosteric inhibitors of BCR-ABL1 be used upfront to prevent evolution of resistance mutants such as *T315I*? • Should any predictors of TFR be incorporated into clinical decision-making or trial design? • Is TKI dose reduction prior to discontinuation worth exploring further? • What are 3 key takeaways from this session?	
4.45 PM – 4.55 PM 10 min	**CML: Relapsed/Refractory and New Targets** (including mutation testing)	Jerald Radich, MD
4.55 PM – 5.20 PM 25 min	**Key Questions and Topics for Discussion** • What are the barriers to mutation testing in the setting of relapsed/refractory disease, and how do we overcome them? • What trial designs should be employed to investigate new mechanisms of action in CML? • What are 3 key takeaways from this session?	
5.20 PM – 5.30 PM 10 min	*BREAK*	
5.30 PM – 5.40 PM 10 min	**ALL: Genetic Subsets**	Aaron Logan, MD, PhD

5.40 PM – 5.55 PM 15 min	**Key Questions and Topics for Discussion** • What are critical markers that might affect selection of optimal therapies? • To what extent do BCL-2 inhibitors overcome the poor prognosis of Ph-like ALL? • What is the best TKI for Ph-positive ALL? What is the best partner for the TKI (chemo, antibodies, etc)? • What are 3 key takeaways from this session?	
5.55 PM – 6.05 PM 10 min	**ALL: Role of Monoclonal Antibodies and Bispecific Engagers**	Elias Jabbour, MD
6.05 PM – 6.25 PM 20 min	**Key Questions and Topics for Discussion** • What level of evidence do we need for antibodies plus chemotherapy to be the standard of care? • How effective are bispecific antibodies and bispecific engagers in CNS disease? • Have long-term AEs with these agents emerged? • What are the determinants to choose between CAR T cells and monoclonal antibodies/bispecific engagers? • What is the optimal approach to measuring MRD? • Beyond the approval of blinatumomab in MRD-positive disease, how will MRD assessment inform choice of therapy in ALL? • Has the pandemic had any impact on your treatment paradigm or patient's behavior, eg, transplant delay, shift from academic center to community, increased use of outpatient regimens? What might be the impact of these shifts on future treatment and patient characteristics? • What are 3 key takeaways from this session?	
6.25 PM – 6.35 PM 10 min	**ALL: Role of CAR T Cells**	Jae Park, MD
6.35 PM – 6.55 PM 20 min	**Key Questions and Topics for Discussion** • When taking into account the rate of manufacturing failures, and patients who ultimately cannot receive their CAR T cells, what is the ITT efficacy of this approach? • Has the feasibility of autologous T-cell collection changed in the context of the global pandemic? • What is the potential role of CAR T cells in patients >25 years of age with ALL? • How will the relationship between CAR T cells and HSCT evolve? • What are 3 key takeaways from this session?	
6.55 PM – 7.00 PM 5 min	Wrap-Up and Overview	Elias Jabbour, MD

Virtual Meeting Part 2
Date: September 15, 2020
Virtual Start Time (3-hour duration): 5.00 PM EDT/4.00 PM CDT/3.00 PM MDT/2.00 PM PDT

AGENDA

Time (CDT)	Topic	Speaker/Moderator
4.00 PM – 4.05 PM 5 min	**Agenda Review**	Elias Jabbour, MD
4.05 PM – 4.15 PM 10 min	**MDS: Low-Risk Disease**	Guillermo Garcia-Manero, MD
4.15 PM – 4.40 PM 25 min	**Key Questions and Topics for Discussion** • How is luspatercept being integrated and sequenced in the treatment algorithm? • How should genetic testing in MDS be incorporated into risk assessment and/or treatment selection? • What are 3 key takeaways from this session?	
4.40 PM – 4.50 PM 10 min	**MDS: High-Risk Disease**	Rami Komrokji, MD
4.50 PM – 5.15 PM 25 min	**Key Questions and Topics for Discussion** • What magnitude of benefit/toxicity profile would be needed for new agents (eg, ASTX727, APR-246, pevonedistat) to be incorporated into the new first-line standard of care in high-risk MDS? • What are 3 key takeaways from this session?	
5.15 PM – 5.25 PM 10 min	*BREAK*	
5.25 PM – 5.35 PM 10 min	**AML: Patient Subsets** (including ELN classification, prognostic groups, unfit elderly)	Richard Stone, MD
5.35 PM – 5.50 PM 15 min	**Key Questions and Topics for Discussion** • How should revisions in AML classification inform new clinical trial designs? • What is the optimal management of unfit elderly patients? Should all receive a BCL-2 inhibitor? • What are 3 key takeaways from this session?	
5.50 PM – 6.00 PM 10 min	**AML: Targeting FLT3 and BCL-2**	Naval Daver, MD
6.00 PM – 6.20 PM 20 min	**Key Questions and Topics for Discussion** • Will next-generation agents such as gilteritinib replace midostaurin in the first-line setting? Why or why not? • Does the regulatory experience with quizartinib in relapsed/refractory AML inform future trial design?	

	• What are potential partners for BCL-2 inhibitors in addition to HMAs and nucleoside analogs, and what is the optimal approach for combinations? • What implications might the recent failure of the pivotal study for enasidenib have for its conditional approval? • What are 3 key takeaways from this session?	
6.20 PM – 6.30 PM 10 min	**AML: New Therapeutic Targets**	Amir Fathi, MD
6.30 PM – 6.45 PM 15 min	**Key Questions and Topics for Discussion** • Which evolving immunotherapeutic approaches are particularly compelling in AML? • What is the potential for IDH inhibition upfront and/or in combinations? • Is there a target among the immunotherapies that is emerging as a leading target (eg, CD123, CD33, FLT3, CD70) and if so, why? • What are 3 key takeaways from this session?	
6.45 PM – 7.00 PM 15 min	Wrap-Up and Overview	Elias Jabbour, MD